MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
← catalyst calendarNCT06132256 · readout ≤ 41 d
Sponsored by Syndax Pharmaceuticals (industry) · SNDX — their whole pipeline →. With DevPro Biopharma.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
145actual
Sites
78
Countries
Australia, Belgium, Canada +10
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-11 | actual | When the study began enrolling |
| Primary completion | Sep 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-11-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Idiopathic Pulmonary Fibrosis
Interventions
- Drug: Axatilimab — also filed as Niktimvo, SNDX-6352
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFAnnualized rate of decline in morning pre-dose trough forced vital capacity (FVC) (milliliter [mL])
measured Baseline through Week 26
Permalink · SNDX's whole pipeline · Catalyst calendar · Every registered study · What changed